Belimumab is a monoclonal antibody binding to a cytokine that is considered important in SLE pathogenesis, that is, B-Lymphocyte Stimulator (BLyS), also known as B cell activating factor belonging to the tumour necrosis factor family (BAFF). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.